{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:34:43Z","timestamp":1753893283858,"version":"3.41.2"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81702895"],"award-info":[{"award-number":["81702895"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To study the efficacy of interval debulking surgery (IDS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) compared to IDS alone for the treatment of ovarian cancer after neoadjuvant chemotherapy (NACT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective study of patients with stage IIIC\/IV high-grade serous ovarian carcinoma who underwent surgery at our center from January 2018 to December 2019. Patients who underwent IDS after NACT with (<jats:italic>N<\/jats:italic>\u2009=\u200920) or without (<jats:italic>N<\/jats:italic>\u2009=\u200942) HIPEC were included. HIPEC was administered after surgery and was combined with 1\u20132 courses of intraperitoneal hyperthermic perfusion with normal saline only. We analyzed clinical information and outcomes for the two groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median progression-free survival (PFS) was 14.05 months in the IDS plus HIPEC group and 12.97 months in the IDS group (<jats:italic>P<\/jats:italic>\u2009=\u20090.597). The median overall survival (OS) was not reached. After adjustment for age between the two groups, the differences in PFS and OS remained nonsignificant. The change ratio of postoperative CA-125 to preoperative CA-125 was 0.66 in the IDS plus HIPEC group and 0.53 in the IDS group (<jats:italic>P<\/jats:italic>\u2009=\u20090.341). The difference in human epididymis protein 4 (HE-4) change ratio between the two groups was nonsignificant (<jats:italic>P<\/jats:italic>\u2009=\u20090.225). No significant difference was observed in the occurrence of grade 3 and 4 adverse events between the two groups (<jats:italic>P<\/jats:italic>\u2009=\u20090.201).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>After NACT, IDS plus HIPEC did not show significant PFS and tumor index change ratio benefits over IDS alone in patients with primary ovarian cancer. Further investigations are needed to assess the role of HIPEC in the treatment of ovarian cancer.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fsurg.2022.997344","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T04:21:41Z","timestamp":1662956501000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["No obvious advantage of hyperthermic intraperitoneal chemotherapy after interval debulking surgery in the treatment of advanced ovarian cancer: A retrospective study"],"prefix":"10.3389","volume":"9","author":[{"given":"Mengmeng","family":"Lyu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianqian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.21037\/atm.2020.03.156","article-title":"Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?","volume":"8","author":"Boussios","year":"2020","journal-title":"Ann Transl Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.21037\/atm-20-1683","article-title":"Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going?","volume":"8","author":"Moschetta","year":"2020","journal-title":"Ann Transl Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/s0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e15563","DOI":"10.7759\/cureus.15563","article-title":"Past, present, and future of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer","volume":"13","author":"Mishra","year":"2021","journal-title":"Cureus"},{"key":"B6","doi-asserted-by":"publisher","first-page":"100149","DOI":"10.1016\/j.esmoop.2021.100149","article-title":"Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"6","author":"Kim","year":"2021","journal-title":"ESMO Open"},{"key":"B7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.surge.2020.08.016","article-title":"Survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a systematic review and discussion of latest controversies","volume":"19","author":"Flood","year":"2020","journal-title":"Surgeon"},{"key":"B8","doi-asserted-by":"publisher","first-page":"S182","DOI":"10.21037\/jgo-20-130","article-title":"Narrative review of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced ovarian cancer: a critical reappraisal of the current evidence","volume":"12","author":"Spiliotis","year":"2021","journal-title":"J Gastrointest Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e18355","DOI":"10.1097\/md.0000000000018355","article-title":"Selection of patients with ovarian cancer who may show survival benefit from hyperthermic intraperitoneal chemotherapy: a systematic review and meta-analysis","volume":"98","author":"Kim","year":"2019","journal-title":"Medicine"},{"key":"B10","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","article-title":"Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study","volume":"22","author":"Spiliotis","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.1002\/cncr.32496","article-title":"Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer","volume":"125","author":"Vergote","year":"2019","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"5520","DOI":"10.1200\/JCO.2017.35.15_suppl.5520","article-title":"Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer","volume":"35","author":"Lim","year":"2017","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ygyno.2014.11.072","article-title":"A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer","volume":"136","author":"Chiva","year":"2015","journal-title":"Gynecol Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1136\/ijgc-2018-000066","article-title":"Pre-operative assessment of intra-abdominal disease spread in epithelial ovarian cancer: a comparative study between ultrasound and computed tomography","volume":"29","author":"Alc\u00e1zar","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the gynecological cancer intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ygyno.2013.04.001","article-title":"Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a gynecologic oncology group study","volume":"130","author":"Landrum","year":"2013","journal-title":"Gynecol Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1200\/jco.18.01568","article-title":"Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG oncology\/gynecologic oncology group study","volume":"37","author":"Walker","year":"2019","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e2013940","DOI":"10.1001\/jamanetworkopen.2020.13940","article-title":"Evaluation of cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for stage III epithelial ovarian cancer","volume":"3","author":"Lei","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B22","doi-asserted-by":"publisher","first-page":"437","DOI":"10.5468\/ogs.21093","article-title":"Hyperthermic intraperitoneal chemotherapy as consolidation treatment of advanced stage ovarian cancer","volume":"64","author":"Ko","year":"2021","journal-title":"Obstet Gynecol Sci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ygyno.2020.11.035","article-title":"HIPEC After neoadjuvant chemotherapy and interval debulking is associated with development of platinum-refractory or -resistant disease","volume":"161","author":"Jou","year":"2021","journal-title":"Gynecol Oncol"},{"key":"B24","first-page":"74","article-title":"The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a prospective study","volume":"16","author":"Spiliotis","year":"2011","journal-title":"J BUON"},{"key":"B25","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1245\/s10434-017-6151-5","article-title":"Comment on: surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study","volume":"24","author":"Batista","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.21037\/gs-20-335","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer recurrence: systematic review and meta-analysis","volume":"9","author":"Cianci","year":"2020","journal-title":"Gland Surg"},{"key":"B27","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s13304-018-0600-y","article-title":"Cytoreductive surgery followed by HIPEC repetition for secondary ovarian cancer recurrence","volume":"71","author":"Cianci","year":"2019","journal-title":"Updates Surg"},{"key":"B28","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jmig.2014.11.008","article-title":"Minimally invasive secondary cytoreduction plus HIPEC versus open surgery plus HIPEC in isolated relapse from ovarian cancer: a retrospective cohort study on perioperative outcomes","volume":"22","author":"Fagotti","year":"2015","journal-title":"J Minim Invasive Gynecol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1245\/s10434-015-4991-4","article-title":"Hyperthermic intraperitoneal chemotherapy after secondary cytoreduction in epithelial ovarian cancer: a single-center comparative analysis","volume":"23","author":"Baiocchi","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1245\/s10434-020-09095-0","article-title":"The effect of pancreatoduodenectomy plus intraperitoneal hyperthermic perfusion on resectable pancreatic head cancer: cohort study","volume":"28","author":"Feng","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.3892\/ijo.27.5.1321","article-title":"EIPL (Extensive intraoperative peritoneal lavage) therapy significantly reduces peritoneal recurrence after pancreatectomy in patients with pancreatic cancer","volume":"27","author":"Yamamoto","year":"2005","journal-title":"Int J Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1186\/s12885-021-08507-y","article-title":"Dense hyperthermic intraperitoneal chemotherapy with cisplatin in patients with stage III serous epithelial ovarian cancer: a retrospective study","volume":"21","author":"He","year":"2021","journal-title":"BMC Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"44","DOI":"10.21037\/cco-20-49","article-title":"Role of hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"9","author":"Medina-Castro","year":"2020","journal-title":"Chin Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.21037\/atm-20-1486","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer: Qui Bono?","volume":"8","author":"Spiliotis","year":"2020","journal-title":"Ann Transl Med"}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2022.997344\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T04:21:44Z","timestamp":1662956504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2022.997344\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":34,"alternative-id":["10.3389\/fsurg.2022.997344"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2022.997344","relation":{},"ISSN":["2296-875X"],"issn-type":[{"type":"electronic","value":"2296-875X"}],"subject":[],"published":{"date-parts":[[2022,9,12]]},"article-number":"997344"}}